Neostem Inc (NASDAQ:NBS)

CAPS Rating: 3 out of 5

Recs

0
Player Avatar neoexmnist (76.02) Submitted: 12/18/2012 7:33:14 AM : Outperform Start Price: $6.50 NBS Score: -49.40

NeoStem is projected to have their first treatment commercialized in 2017.

Featured Broker Partners


Advertisement